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Abstract
Pharmacological inhibition of the sonic hedgehog (SHH) pathway can be beneficial 
against certain cancers but detrimental in others. Adamantinomatous craniopharyngioma 
(ACP) is a relevant pituitary tumour, affecting children and adults, that is associated 
with high morbidity and increased mortality in long-term follow-up. We have previously 
demonstrated overactivation of the SHH pathway in both human and mouse ACP. Here, 
we show that this activation is ligand dependent and induced by the expression of SHH 
protein in a small proportion of tumour cells. We investigate the functional relevance 
of SHH signalling in ACP through MRI-guided preclinical studies using an ACP mouse 
model. Treatment with vismodegib, a clinically approved SHH pathway inhibitor, results 
in a significant reduction in median survival due to premature development of highly 
proliferative and vascularised undifferentiated tumours. Reinforcing the mouse data, 
SHH pathway inhibition in human ACP leads to a significant increase in tumour cell 
proliferation both ex vivo, in explant cultures, and in vivo, in a patient-derived xenograft 
model. Together, our results demonstrate a protumourigenic effect of vismodegib-
mediated SHH pathway inhibition in ACP.
Introduction
Adamantinomatous craniopharyngiomas (ACPs) are 
benign tumours of the sellar region that are associated 
with high morbidity and increased mortality in long-
term follow-up. They constitute the most common non-
neuroepithelial brain tumour in children (peak diagnosis 
at 5–14  years) and can also develop in adults (peak 
diagnosis 50–74 years). ACPs display clinically aggressive 
behaviour by invading vital surrounding structures such 
as the hypothalamus and optic chiasm, which complicates 
surgical resection leading to severe postoperative sequelae. 
Currently, there are no targeted molecular treatments for 
these patients (Karavitaki & Wass 2008, Muller et al. 2017) 
The majority of human ACPs carry somatic mutations 
in CTNNB1, which result in the expression of a 
degradation-resistant form of β-catenin and activation 
of the WNT/β-catenin pathway (Sekine et  al. 2002, 
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Kato et al. 2004, Buslei et al. 2005, Brastianos et al. 2014, 
Apps et al. 2018).
The expression of functionally equivalent mutant 
β-catenin in either pituitary embryonic precursors 
(Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice) or adult pituitary stem cells 
(Sox2CerERT2/+;Ctnnb1lox(ex3)/+ mice) results in the formation 
of tumours resembling human ACP (Gaston-Massuet et al. 
2011, Andoniadou et al. 2013). In both models, tumoural 
pituitaries show the presence of β-catenin-accumulating 
cells forming clusters, which share a common molecular 
signature with those found in humans (Gonzalez-Meljem 
et al. 2017). Our initial studies revealed the upregulation 
of the sonic hedgehog (SHH) pathway in both mouse 
and human ACP, a finding confirmed subsequently by 
independent research (Andoniadou et  al. 2012, Gomes 
et  al. 2015, Gump et  al. 2015, Holsken et  al. 2016). 
However, the biological function of the SHH pathway in 
ACP pathogenesis remains unknown to date.
The SHH pathway has been implicated in 
the pathogenesis of multiple cancers including 
medulloblastoma, basal cell carcinoma, breast, colon and 
pancreatic ductal adenocarcinoma (PDAC) (Rimkus et  al. 
2016). While SHH pathway inhibition has proven beneficial 
against basal cell carcinoma (Sekulic et al. 2012, 2017), it 
has proven detrimental in other cancers, such as PDAC, 
where enhanced tumour progression and aggressiveness 
was observed in both preclinical and clinical trials (Madden 
2012, Catenacci et al. 2015). These discrepancies between 
favourable or unfavourable outcomes after SHH pathway 
inhibition prompted us to assess the functional relevance 
of the SHH pathway in human ACP. Our preclinical 
research demonstrates that inhibition of the SHH pathway 
using vismodegib is not beneficial and is therefore 
contraindicated in human patients.
Materials and methods
Mice
All experimental protocols were monitored and approved 
by The Institute of Cancer Research Animal Welfare and 
Ethical Review Body, in compliance with guidelines 
specified by the UK Home Office Animals (Scientific 
Procedures) Act 1986, the United Kingdom National 
Cancer Research Institute Guidelines for the Welfare of 
Animals in Cancer Research (Workman et  al. 2010) and 
the ARRIVE guidelines (Karp et  al. 2015). Animals were 
monitored daily and were killed at defined humane end 
points (i.e. prior to the mice showing signs of severe 
health deterioration or 20% weight loss). Patient-derived 
xenografts were generated as previously described (Stache 
et al. 2015). All mice were housed in compliance with the 
Home Office Code of Practice. Mice were kept on a 12-h 
light/darkness cycle and fed ad libitum with a complete 
pelleted mouse diet and with constant access to water.
Hesx1Cre/+ mice have been previously described 
(Andoniadou et  al. 2007). The line was maintained 
on a C57BL/6J background for over 50 generations. 
Heterozygotes were used for crosses with Ctnnb1lox(ex3)/+ 
mice (Harada et  al. 1999) to obtain Hesx1Cre/+ and 
Ctnnb1lox(ex3)/+ mice (Gaston-Massuet et  al. 2011). For 
xenografts, we used NIH nu/nu were bred in our local 
Biological Services Unit.
Drug administration
Four-week-old male Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice were 
administered vismodegib (Roche) or vehicle in 2% 
DMSO, 30% PEG 300, 5% Tween 80, ddH2O via oral 
gavage at a dose of 100 mg/kg of body weight twice a day 
(approximately 07:30 h and 16:00 h).
Human samples
Experiments using human samples were covered by the 
ethical approval 14 LO 2265 or the ethical approval of 
specific tissue banks. Human ACP samples were kindly 
provided by the GOSH Histopathology Department.
Ex vivo culture of ACP human tumours
Explant cultures were performed as previously described 
(Apps et  al. 2018). Small pieces from three different 
human ACP tumours (approximately 1 mm3; four 
replicates per tumour) were placed on 0.2 μM Whatman 
filters (SLS) in 24-well plates containing 500 μL of media 
(DMEM-F12 (Gibco), 1% Pen/Strep (Sigma) and 1% FBS 
(PAA)) supplemented with either Vismodegib 100 μM 
(Selleckchem) or vehicle (DMSO) and medium was 
changed every 24 h. After 72 h, tumour pieces were passed 
through a Qiashredder column (Qiagen) and processed 
for total RNA extraction using the RNeasy Micro kit 
(Qiagen). Approximately 1 μg of total RNA was reverse-
transcribed to cDNA using the Transcriptor First-Strand 
cDNA Synthesis Kit and random hexamers (Roche).
Magnetic resonance imaging
Multi-slice T2-weighted images were acquired using a 7 T 
Bruker microimaging system with a 3 cm birdcage coil over 
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a 2.5 cm field-of-view (RARE; TR = 4500 ms, TEeff = 36 ms). 
MRI was performed on the final day of treatment and at 
least every 2 weeks thereafter, until mice presented with 
neurological symptoms or lost condition (Boult et  al. 
2018).
Histology and immunostaining on 
histological sections
Immunohistochemistry and immunofluorescence were 
carried out using the same antibodies, concentrations and 
retrieval conditions as previously described (Andoniadou 
et al. 2013, Gonzalez-Meljem et al. 2017, Apps et al. 2018). 
Immunostaining of SHH protein was also conducted 
as previously described (Carreno et  al. 2017). Section 
immunostaining was performed as previously described 
(Andoniadou et  al. 2012). Briefly, slides were de-waxed 
in HistoClear, re-hydrated from 100% EtOH to double 
distilled MilliQ water and underwent antigen retrieval 
in an antigen retrieval unit (BioCare Medical Decloaking 
Chamber NXGEN) for 2 min at 95°C. Slides were then 
washed in 1× PBT, which consists of 1× PBS and 0.1% Triton 
X-100. Histological slides were then blocked for 1 h at RT 
in blocking buffer and 10% heat inactivated sheep serum 
(HISS), blocking buffer contains 0.1% Triton X-100, 0.15% 
glycine, 2 mg/mL BSA in 1× PBS. SHH was visualised using 
the TSA Plus Fluorescein System (Perkin Elmer), following 
the manufacturer’s protocol. Primary and secondary 
antibodies were diluted into blocking buffer and 1% 
HISS. Sections were counter stained with 4′,6-diamidino-
2-phenylindole (DAPI) for 5 min (1:10,000, Sigma) and 
mounted onto coverslips with VectaMount (Vector 
Laboratories). For immunohistochemical stainings, 
slides were first incubated with an Avidin-Biotinylated 
Peroxidase Complex (Vector). Chromogenic detection 
was then conducted by addition of 3,3′-diaminobenzidine 
(DAB, Vector) for 2–5 min and then counterstained with 
Mayer’s hematoxylin (Sigma).
Quantitative analysis of 
immunofluorescent stainings
The proliferative and mitotic indexes were calculated as a 
percentage of the Ki67 positive or p-histone H3-positive 
cells out of the total of DAPI-stained nuclei, respectively. 
Cells were counted using ImageJ, a Gaussian filter was 
applied and the cell counter plugin was used. Endomucin-
positive staining in pixels was analysed as a percentage of 
the total area using ImageJ.
Quantitative reverse transcriptase PCR (qRT-PCR)
Quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR) amplification was performed on 
murine anterior pituitaries and human tumour samples as 
previously described (Gonzalez-Meljem et al. 2017, Apps 
et  al. 2018). RNA was extracted from tissues using the 
RNeasy Micro or Mini Kit (Qiagen). RNA was quantified 
using 1.2 µL of extracted RNA on a NanoDrop 1000 
Spectrophotometer. cDNA was retro-transcribed from 1 µg 
of extracted RNA using the iScript Reverse Transcription 
Supermix for RT-qPCR kit (BioRad). Thermocycling 
conditions were performed according to manufacturer’s 
instructions. qRT-PCR was performed using 64 iTaq 
Universal SYBR Green Supermix (BioRad), thermocycling 
conditions were performed according to manufacturer’s 
instructions. Analysis was performed using CFX Manager 
BioRad software. Three microliters of the amplified 
product was run by gel electrophoresis in order to visualise 
correct product size. Relative quantitation of the target 
gene was performed against glyceraldehyde 3-phospate 
dehydrogenase (Gapdh) as the housekeeping gene in 
murine and human samples. The average Ct values were 
calculated for the control and test sample genes. ΔCt was 
calculated by subtracting the Ct of the housekeeping 
gene from the target gene Ct values for both test and 
control samples. ΔΔCt was then calculated as the ratio 
of expression between the test and control samples. 
Finally, the fold change was calculated by 2−ΔΔCt for 
each sample. SHH, GLI1 and PTCH1 levels were measured 
using the Qiagen QuantiTect Primers (Cat. QT00205625, 
QT00060501, QT00075824). Murine Shh and Gli1 levels 
were measured with the Qiagen QuantiTect Primers 
(Cat. QT00122479, QT00173537).
Murine pituitary adherent clonogenic cell culture
Clonogenic assays were performed on murine tumoural 
pituitaries as described (Gaston-Massuet et  al. 2011, 
Carreno et al. 2017, Haston et al. 2017). Pituitaries were 
dissected using aseptic forceps and the posterior pituitary 
was removed. After mincing with forceps, the remaining 
tissue was placed into 200 µL of enzyme mix, which 
consisted of Hanks’ Balanced Salt Solution (HBSS, Gibco), 
0.5% w/v Collagenase (Worthington), 50 µg/mL DNAase 
I (Worthington), 1% Fungizone and 0.1× trypsin (Sigma), 
for 4 h in a 37°C water bath. HBSS was added to make a final 
volume of 500 µL post incubation and the solution was 
triturated into a single-cell suspension. Once single-cell 
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suspensions were achieved, 9.5 mL of HBSS was added 
and the cells spun down for 5 min at 200 g. Cells were 
re-suspended in growth medium, which consisted of 
DMEM/F12, 5% FCS, 1% PenStrep, 20 ng/mL human 
recombinant bFGF (R&D Systems) and 50 ng/mL cholera 
toxin. Cells were plated at clonal density in a six-well 
plate at 2000, 4000 and 8000 cells per well. Fresh bFGF 
was added after 2 days, and medium was then changed on 
the third day and every 3 days after colony establishment. 
Colony counting was conducted after 7 days in culture. 
Colonies were washed with PBS and fixed for 20 min with 
4% PFA, washed again in PBS and stained with Harris 
haematoxylin for 15 min at room temperature.
Xenografts
Patient-derived xenograft (PDX) mice were generated 
as described (Stache et  al. 2015). NIH nu/nu mice were 
anesthetised with 2% isoflurane and the top of the head 
was disinfected. An ~1 cm incision was made to the skin 
of the head to expose the skull. The incision was treated 
with 10% xylocaine. Thrity percent H2O2 was applied to 
the skull to remove the periosteal membranes. A 1 mm 
in diameter hole was bored into the skull, 1 mm left and 
1 mm posterior of the Bregma. Human ACP tumour tissue 
was dissected into 1–2 mm3 pieces, and these were inserted 
into the cortex using forceps. The skin was then sutured 
to close the wound. The surgical area was disinfected 
again. Mice were placed on a heated mat and monitored 
until recovery.
Statistics
Independent unpaired t-tests and one-way ANOVA were 
used to analyse the data from the qRT-PCR and proliferative 
assays using GraphPad Prism. Immunofluorescence was 
analysed using Image J. P < 0.05 was considered statistically 
significant. The ‘n’ value indicated throughout the text 
refers to number of biological replicas, that is, different 
mice, pituitaries or tumour samples. Technical replicas, 
that is, number of repeats for the same sample, were three 
for the qRT-PCR experiments. In general, we have not 
performed power calculations to estimate the sample size. 
In most of the quantitative experiments, we have used at 
least three biological replicas, often 6 or more. Only in 
the xenotransplantation experiments, have we used two 
human tumours. Many of these experiments use embryos 
or mouse and human tumours, which are samples not 
readily available. For the preclinical trial, we performed 
a power calculation, based on pilot experiments. A total 
of 12 mice per group were decided to compensate for 
sample attrition.
Results
SHH protein is expressed in mouse and human ACP 
leading to the paracrine activation of the 
SHH pathway
The expression of SHH at the mRNA level in the 
β-catenin-accumulating cell clusters and activation of 
the SHH pathway in human ACP have been thoroughly 
documented (Andoniadou et al. 2012, Gomes et al. 2015, 
Gump et al. 2015, Holsken et al. 2016). However, the SHH 
protein has not been identified in human or mouse ACP. 
Double immunostaining revealed the co-localisation of 
β-catenin and SHH protein in clusters of both human 
and mouse ACP (Fig.  1A and B, respectively). qRT-PCR 
revealed that Shh mRNA expression was increased in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ mutant mice relative to age-
matched Ctnnb1lox(ex3)/+ controls at one (134 ± 1-fold), four 
(125 ± 1-fold) and eight (68-fold) weeks of age (n = 3–5 
samples/group, P < 0.0001, Student’s t-test). The expression 
of the SHH pathway target gene Gli1 was also upregulated 
at all stages in mutant pituitaries compared to controls 
(1  week: 15.3 ± 0.2-fold P = 0.018; 4  weeks: 8.7 ± 0.1-fold; 
8 weeks: 4.9 ± 0.3-fold; n = 3–5 samples/group; P < 0.0001; 
Student’s t-test) (Fig. 1C). Note that a similar decreasing 
trend in Gli1 and Shh mRNA expression was observed 
over time (Fig. 1C). Since mutations in the components 
of the SHH pathway have not been identified in humans 
(Brastianos et  al. 2014, Apps et  al. 2018) or mouse ACP 
(Gonzalez-Meljem et al. 2017), our data suggest that the 
SHH pathway is activated in ACP in a ligand-dependent 
manner.
Inhibition of the SHH pathway in a genetically 
modified murine model of ACP results in reduced 
survival and increased tumourigenesis
To assess the role of the SHH pathway in the pathogenesis 
of ACP, we performed a MRI-guided preclinical trial 
using the smoothened (SMO) inhibitor vismodegib in 
the Hesx1Cre/+;Ctnnb1lox(ex3)/+ ACP mouse model. Clinical 
trials have demonstrated that treatment with vismodegib 
results in long-term responses in patients with advanced 
basal cell carcinoma (Sekulic et al. 2012, 2017), and this 
inhibitor is currently being used in numerous ongoing 
clinical trials for other human cancers (Rimkus et al. 2016).
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Pharmacokinetic studies in mice have shown that 
serum levels of vismodegib decrease after 12 h and 
suggested that a twice-a-day dosing regimen leads to 
more permanent pathway inhibition (Wong et al. 2011). 
An administration dose of 100 mg/kg of body weight was 
chosen as it is the highest non-toxic dose identified in the 
literature (Wong et al. 2011). A dosing regimen of twice 
a day for 7 days was chosen as it was hypothesised that 
any pharmacological effect on the SHH pathway would 
be evident after 7  days. This dosing regimen revealed 
an overall reduction in relative Gli1 mRNA levels in the 
vismodegib-treated tumoural pituitaries compared to 
vehicle-treated control pituitaries, which did not reach 
significance (vehicle: 2.5-fold, vismodegib: 1.5-fold, n = 8; 
P = 0.35, ANOVA) (Fig.  1D). We noted a high degree of 
variability in Gli1 expression levels in the vehicle-control 
group as well as untreated Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice 
(2.1-fold relative to Ctnnb1lox(ex3)/+ controls, n = 7 mice), 
with some animals showing much higher Gli1 levels than 
others, suggesting a similarly inherent heterogeneity in 
the ACP mouse model to that reported in human ACP 
(Gomes et  al. 2015). Gli1 expression mRNA levels were 
lower and more uniform with vismodegib treatment. We 
did not evaluate GLI1 expression at the protein level.
For the preclinical trial, Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice 
were dosed twice a day with 100 mg/kg of body weight of 
vismodegib or vehicle (11 and 12 mice, respectively) for 
a total of 56 doses over 28 days (the maximum allowed 
by UK animal welfare authorities) (Fig. 1E). Treated mice 
were monitored by MRI and killed at a defined humane 
endpoint (i.e. prior to the mice showing signs of severe 
health deterioration or 20% weight loss). Surprisingly, 
a significant decrease in survival was observed in the 
vismodegib-treated animals in comparison with vehicle-
treated controls (11.9  weeks vs 33.3  weeks; P = 0.049, 
log-rank test) (Fig. 1F).
T2-weighted MRI throughout the trial up until each 
humane end point for both treated and vehicle groups 
demonstrated no significant differences in tumour 
phenotype and size of total and solid tumour volume 
(Fig.  2A). In other words, the vismodegib-treated mice 
did not develop larger tumours; at the humane end 
point, tumours were similar in size. MRI revealed tumour 
enlargement and heterogeneity in both groups prior 
to the development of hyperintense cysts, expansion 
of a solid portion of the tumour and presentation of 
hypointense haemorrhagic regions, consistent with our 
previous imaging studies (Boult et al. 2018). Furthermore 
histologically, tumours showed no gross morphological 
differences between the groups (Fig. 2B). However, the MRI 
data revealed that the doubling time of the solid component 
of the tumours was shorter in vismodegib-treated tumours 
compared with controls (vismodegib: 8.1 ± 1  days; n = 6; 
vehicle: 15.3 ± 3  days; n = 7; P = 0.044; Student’s t-test) 
(Fig. 2F). In agreement with these observations, the Ki67 
proliferative index was increased in the vismodegib-
treated group (41.3 ± 7%, n = 10) compared with controls 
(27.4 ± 5.5%, n = 9) (P = 0.0002, Student’s t test) (Fig. 2C). 
The mitotic index, measured by phospho-Histone H3 
(pHH3) immunofluorescence, was also increased in the 
vismodegib-treated group (vismodegib: 6.5 ± 3%; n = 10; 
vehicle: 3.6 ± 0.8%; n = 9; P = 0.016; Student’s t-test) (Fig. 2D). 
Vismodegib treatment led to increased vasculogenesis, 
as assessed by immunofluorescence staining against the 
endothelial marker endomucin (fluorescent area: 7.8 ± 2% 
in vismodegib-treated group; 5.4 ± 1.4% in control group; 
n = 6; P = 0.0319; Student’s t-test) (Fig. 2E). Together, these 
results suggest that chemical SHH pathway inhibition 
using vismodegib in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice results 
in the formation of aggressive tumours.
Vismodegib-treated Hesx1Cre/+;Ctnnb1lox(ex3)/+ mouse 
pituitaries develop tumours prematurely and show 
increased numbers of clonogenic cells
We hypothesised that inhibiting the SHH pathway could 
lead to an increase in the number of cells with clonogenic 
tumour cells within, potentially tumour-initiating cells. 
Four-week-old Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice were treated 
with either vismodegib (100 mg/kg of body weight) or 
vehicle for 7 days, after which tumoural pituitaries were 
dissected and subjected to either histological analysis 
or assessment of the clonogenic potential as previously 
described (Gaston-Massuet et al. 2011, Andoniadou et al. 
2013) (Fig. 3A). H&E staining identified tumour lesions in 
vismodegib-treated Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries (3/3 
pituitaries, Fig.  3B, arrows), which were not present in 
the vehicle-treated mice (0/3 pituitaries). These tumoural 
lesions were synaptophysin negative, suggesting loss of 
differentiation into hormone-producing cells (Fig.  3C), 
consistent with previous observations in mouse and 
human ACP. Furthermore, vismodegib-treated tumoural 
pituitaries showed a higher Ki67 proliferative index 
compared with controls (controls: 3 ± 1.2%; vismodegib: 
8.8 ± 1.0%; n = 3; P = 0.0037; Student’s t-test) (Fig.  3D). 
We have previously shown the expansion of clonogenic 
SOX2-positive tumour cells in the Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
mice (Gaston-Massuet et al. 2011, Andoniadou et al. 2013). 
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Figure 1
Inhibition of the SHH pathway in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice, a murine model of human adamantinomatous craniopharyngioma (ACP), results in reduced 
median survival. (A) Double immunofluorescence on formalin-fixed paraffin-embedded (FFPE) histological sections of human ACP showing the 
expression of SHH in the β-catenin-accumulating cell clusters. Scale bar: 25 μm. (B) Double immunofluorescence on FFPE histological sections of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumoural pituitaries revealing the expression of SHH in the β-catenin-accumulating cell clusters at specific time points of postnatal 
life. Note the overall reduction in SHH staining from 1 to 8 weeks of age. Scale bar: 50 μm. (C) qRT-PCR analysis showing the up-regulation of Shh and the 
target pathway gene Gli1 in the tumoural pituitaries of the Hesx1Cre/+;Ctnnb1lox(ex3)/+ ACP mouse model compared with Ctnnb1lox(ex3)/+ controls at specific ages 
(Shh: 1 week, 134-fold; 4 weeks, 125-fold; 8 weeks, 68-fold; Gli1: 1 week, 15.3-fold, P = 0.018; 4 weeks, 8.7-fold, P < 0.0001; 8 weeks, 4.9-fold, P < 0.0001 
(n = 3–5 tumoural pituitaries per time point, Student’s t-test). (D) qRT-PCR analysis of Gli1 expression levels in Hesx1Cre/+;Ctnnb1loxex3/+ tumoural and 
Ctnnb1lox(ex3)/+ control pituitaries treated twice daily with vismodegib (100 mg/kg) for 1 week in comparison with vehicle-treated and untreated mice. There 
is an overall reduction in Gli1 expression levels upon vismodegib treatment, which does not reach significance possibly due to the marked variability in 
Gli1 expression levels in the untreated and vehicle treated controls (untreated: 2.1-fold, n = 7 mice; vehicle: 2.5-fold, n = 8 mice; vismodegib: 1.5-fold, n = 8 
mice; P = 0.35, One-way ANOVA). (E) Schematic diagram of the preclinical trial. Age-matched Hesx1Cre/+;Ctnnb1loxex3/+ male mice are dosed twice daily with 
100 mg/kg vismodegib (11 mice) or vehicle (12 mice) for 28 days starting around 4–5 weeks of age (56 doses). At the end of treatment, mice are left 
untreated and monitored by MRI every 2 weeks and at the humane end point. (F) Kaplan–Meier analysis showing a reduction in median survival in the 
vismodegib-treated (11.9 weeks, n = 11, red line) relative to the vehicle-treated mice (33.3 weeks, n = 12, blue line; P = 0.049, Mantel–Cox (log-rank) test). 
Data represent the mean ± s.d.
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Immunofluorescent staining revealed an elevation 
in SOX2 expression in the vismodegib-treated 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries compared with vehicle-
treated controls. Moreover, dissociation of tumoural 
pituitaries into single-cell suspensions and culture in stem 
cell-promoting media showed a significant increase in the 
numbers of colonies in vismodegib-treated animals relative 
to controls (vehicle: 2597 ± 98; vismodegib: 4924 ± 167; 
n = 3; P = 0.0003; Student’s t-test) (Fig. 3E and F). Currently, 
there is no ACP primary cell culture that maintains the 
Figure 2
Highly proliferative and vascularised tumours are formed upon treatment with vismodegib in the Hesx1Cre/+;Ctnnb1lox(ex3)/+ ACP mouse model. (A) Axial 
T2-weighted MRI scans of vismodegib and vehicle-treated Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice at the level of the brain (two examples of each are shown, labels 
indicate days after the end of treatment). Note the expansion of the pituitary to form a solid tumour component (arrows) and the development of 
hyperintense cysts and hypointense haemorrhagic regions in both vehicle and vismodegib-treated groups. (B) Hematoxylin–eosin (H&E) staining of FFPE 
histological sections of Hesx1Cre/+;Ctnnb1loxex3/+ tumours showing similar histology between experimental groups. Immunofluorescence revealing the 
increased expression of Ki67 (proliferative marker), pHH3 (mitotic marker) and Endomucin (endothelial marker) in vismodegib-treated tumours 
compared with the vehicle-treated controls. Scale bar: 50 μm. (C) (vehicle: 27.4 ± 5.5%, n = 9 tumours; vismodegib: 41.3 ± 7.%, n = 10 tumours; P = 0.0002, 
Student’s t-test, 15,600 DAPI +ve nuclei counted). (D) The mitotic index (fraction of pHH3+ve cells out of total DAPI+ve cells) is elevated upon vismodegib 
treatment (vehicle: 3.6 ± 0.8%, n = 9 tumours; vismodegib: 6.5 ± 3%; n = 10 tumours; P = 0.016, Student’s t-test, 16,700 DAPI +ve nuclei counted). (E) 
Vasculature is increased in the vismodegib-treated group as assessed by immunofluorescence against Endomucin (total fluorescent area: vehicle: 
5.4 ± 1.4%; vismodegib: 7.8 ± 2%; n = 6 tumours per group; P = 0.0319, Student’s t-test). (F) Doubling time of the solid component of the tumours, as 
calculated from contiguous MRI scans, is reduced by 47% upon vismodegib treatment (vehicle: 15.3 ± 3 days, n = 7 tumours; vismodegib: 8.1 ± 1 days, 
n = 6 tumours; P = 0.044, Student’s t-test). Data represent mean ± s.d.
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mutation sustaining cells throughout passages. Together, 
these results suggest that the inhibition of the SHH 
pathway leads to an increase in clonogenic tumour cells, 
with increased proliferative capacity, which promotes the 
development of premature tumour lesions (Fig. 3G).
Inhibition of the SHH pathway in human ACP 
tumours leads to increased proliferation
Finally, we assessed the relevance of the murine studies in 
human ACP. Small pieces of human ACP tumours (1–2 mm3) 
were cultured ex vivo in the presence of vismodegib or 
vehicle, and after 3 days, the tissue was analysed (Fig. 4A) 
(Apps et al. 2018). Vismodegib treatment resulted in the 
overall downregulation of the SHH pathway, as assessed 
by qRT-PCR against GLI1, PTCH1 and SHH (Fig.  4B), 
and the concomitant increase of the proliferative index 
(38.7 ± 12%) relative to the vehicle controls (5.1 ± 3%; n = 3; 
P = 0.0085; Student’s t-test) (Fig. 4C and D). To assess the 
effects of vismodegib in vivo, small fragments of human 
ACP were engrafted into the brains of 20 immunodeficient 
mice (Fig.  4E). After 3  months, mice were divided into 
two groups (10 mice/group) and administered 100 mg/kg 
of body weight of vismodegib or vehicle, twice a day for 
3 weeks, after which brains were collected for histological 
analysis. Immunofluorescent staining revealed a significant 
increase in the Ki67 proliferative index in vismodegib-
treated xenograft mice (12.7 ± 2%, n = 4) relative to the 
vehicle-treated controls (1.8 ± 0.5%, n = 3) (P < 0.0001, 
Student’s t-test) (Fig. 3F and G).
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Figure 3
Vismodegib treatment results in higher numbers of clonogenic cells and premature formation of tumours. (A) Diagram of the experimental approach. 
Four-week old Hesx1Cre/+;Ctnnb1loxex3/+ male mice are dose twice daily with either vismodegib (100 mg/kg) or vehicle for 1 week, after which pituitaries are 
dissected and analysed both histologically and in a clonogenic assay. (B) H&E staining on FFPE histological sections of vehicle and vismodegib -treated 
mice showing the presence of large tumoural lesions (arrows) and cysts (arrowheads) in vismodegib-treated animals. The control pituitaries show smaller 
cysts (arrowheads) and no tumour lesions are detectable (n = 3 pituitaries per group). This is in agreement with our previous observations of a latency 
period of around 17 weeks for tumour formation (Boult et al. 2018). Scale bar: 100 μm. (C) The premature tumour lesions are Synaptophysin−ve (black 
arrow) by immunohistochemistry, and highly proliferative, as assessed by immnufluorescence against Ki67 (white arrow). (D) Quantitative analysis 
demonstrates the higher Ki67 proliferative index upon vismodegib treatment (vehicle: 3.2 ± 1.2%; vismodegib: 8.8 ± 1.0%, n = 3 pituitaries per group; 
P = 0.0029, Student’s t-test, vehicle = 15,213, vismodegib = 13,300 DAPI +ve nuclei counted). Scale bar: 200 μm. (E) Quantification of the clonogenic 
potential of pituitaries from mice treated with either vehicle or vismodegib (n = 3 pituitaries per group). Note that vismodegib treatment results in drastic 
increase in clonogenic potential of nearly 90% relative to the vehicle controls (vehicle: 2597 ± 98 colonies; vismodegib: 4924 ± 167 colonies, n = 3 
pituitaries per group; P = 0.0003, Student’s t-test). (F) Representative examples of plates seeded with 2000, 4000 and 8000 pituitary cells from vehicle and 
vismodegib-treated Hesx1Cre/+;Ctnnb1loxex3/+ mice. Plates are stained with haematoxylin. (G) Schematic summary of main findings. The expression of 
oncogenic β-catenin in Hesx1Cre/+;Ctnnb1loxex3/+ mice results in formation of β-catenin-accumulating cell clusters, which secrete SHH and activate the 
pathway in surrounding tumour cells inducing a more quiescent phenotype characterised by exit of a proliferative, Ki67+ve state. vismodegib-mediated 
inhibition of the SHH pathway leads to more proliferative and aggressive tumours. All graph bars represent mean ± s.d.
https://doi.org/10.1530/ERC-18-0538
https://erc.bioscientifica.com © 2019 The authors
Printed in Great Britain
Published by Bioscientifica Ltd.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 02/11/2019 01:50:00PM
via University College London
363G Carreno et al. SHH pathway inhibition in 
craniopharyngioma
26:3Endocrine-Related 
Cancer
ve
hi
cl
e
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
vi
sm
od
eg
ib
Ki67/β-Cat/DAPI
A
C D
E
ve
hi
cl
e
vi
sm
od
eg
ib
G
 Human ACP 1  Human ACP 2  Human ACP 3
β-CatKi67
br
br
Human ACP
sample
Human ACP
sample
vehicle
vehicle vehicle vehicle
vehicle
vehicle
vismodegib
vismo vismo vismo
vismo
vismo
Ex vivo culture 
Cut into 
1-2 mm3 cubes
Cut into 
1-2 mm3 cubes
Tumour
engraftment
vismodegib
Treatment
100 mg/kg oral 
2 wk
Grafted tumour 
development
Histological 
analysis
vehicle
Histological analysis
and qRT-PCR
F
0
10
20
30
40
50
60
Pr
ol
ife
ra
tiv
e 
in
de
x 
(%
)
0
2
4
6
8
10
12
14
16
Pr
ol
ife
ra
tiv
e 
in
de
x 
(%
)
 3 mo
**
T
T
*
*
0.000
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
0.050
0.000
0.005
0.010
0.015
0.020
0.025
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
0.0012
0.0014GLI1 PTCH1 SHH
B
***
72 hours
Ki67/β-Cat/DAPI
Figure 4
Inhibition of the SHH pathway leads to increased tumour cell proliferation in both explant cultures and xenograft models of human ACP. (A) Schematic 
diagram of the explant culture experiments. Three ACP tumour samples were cut into 1–2 mm3 cubes and cultured in the presence of vismodegib 
(100 μM) or vehicle (DMSO). Four biological replicates were performed for each analysis (i.e. four pieces of tumours per treatment). (B) qRT-PCR analysis 
showing the overall inhibition of the SHH pathway as assessed by a variable reduction in GLI1, PTCH1 and SHH expression upon vismodegib treatment in 
three human ACP tumours. One sample did not show reduction of GLI1, but both PTCH1 and SHH expression were reduced. (C) Double 
immunofluorescence on FFPE histological sections showing increased expression of Ki67+ve in the human ACP explants cultured in the presence of 
vismodegib relative to the DMSO-treated controls. Scale bar: 25 μm. (D) Quantitative analysis revealing a higher Ki67+ve proliferative index in vismodegib 
compared with vehicle-treated explants (vehicle: 5.1 ± 3%; vismodegib: 38.7 ± 12%; n = 3 tumours per group; P = 0.0085, Student’s t-test, 10,037 DAPI +ve 
nuclei counted). (E) Schematic diagram of the human ACP xenograft experiments. Two human ACP tumours were cut into 1–2 mm3 and implanted into 
the cortex of 20 immunosuppressed mice (11 animals with tumour 1 and 9 with tumour 2). Three months later, mice were randomised into two groups 
of 10 mice each and dosed twice daily with 100 mg/kg vismodegib or vehicle for 21 days, after which brains were dissected and analysed histologically.  
(F) Double immunofluorescent staining revealing the presence of Ki67+ve cells (arrows) in the proximity of β-catenin-accumulating cell clusters (asterisks) 
in both vismodegib and vehicle-treated xenografted human ACP tumours. Scale bar: 25 μm. (G) Quantitative analysis showing an elevation of the Ki67 
proliferative index in the xenografted tumours upon treatment with vismodegib (vehicle: 1.8 ± 0.5%, n = 3 tumour-bearing mice; vismodegib: 12.7 ± 2%, 
n = 4 tumour-bearing mice; P < 0.0001, Student’s t-test, 2332 DAPI +ve nuclei counted). All graph bars represent mean ± s.d.
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Discussion
The main highlight of this research is the demonstration 
that the inhibition of the SHH pathway using vismodegib, 
a well-established SMO inhibitor used in the clinic (De 
Smaele et al. 2010), results in premature tumour formation 
and increased tumour cell proliferation in both genetically 
engineered and patient-derived xenograft mouse models. 
These data suggest that the use of vismodegib and 
potentially other SMO inhibitors is contraindicated in 
ACP patients.
The activation of the SHH pathway in human 
ACP was initially documented from research in the 
Hesx1Cre/+;Ctnnb1loxex3/+ mouse model of ACP. The presence 
of mRNA expression was demonstrated in five human 
ACP tumours (Andoniadou et al. 2012). These results were 
extended further in a larger cohort of tumours by Gomes 
et al., who revealed the expression of GLI1, GLI3, SUFU 
and SMO in human ACP at the protein level (Gomes et al. 
2015). More recently, the activation of the SHH pathway 
has been demonstrated in gene expression analyses of 
ACP (Holsken et al. 2016, Donson et al. 2017, Apps et al. 
2018). Mutations in components of the SHH pathway 
(i.e. loss-of-function mutations in PTCH1 or gain-of-
function mutations in SMO) have not been identified in 
independent sequencing efforts neither in human nor 
in mouse ACP, suggesting that the SHH pathway may 
be activated in a paracrine manner (Theunissen & de 
Sauvage 2009). Here, we extend these observations by 
demonstrating the presence of SHH protein within the 
beta-catenin-accumulating cell clusters, hence reinforcing 
the idea that the SHH pathway is activated in a ligand-
dependent fashion. Of relevance, we have recently 
shown that these clusters contain senescent cells and act 
as signalling hubs within the tumours by activating the 
expression of numerous secreted factors, including SHH, 
FGF, EGF, BMP and TGF beta among others (Gonzalez-
Meljem et al. 2017, Apps et al. 2018).
We show that treatment with vismodegib leads 
to accelerated tumourigenesis with tumours showing 
an elevated proliferation index, increased clonogenic 
potential in vitro and enhanced vascularity. In concordance 
with our preclinical data, research in mouse models of 
other human cancers, in which the activation of the 
SHH pathway is also ligand dependent, has revealed that 
the inhibition of this pathway (e.g. using vismodegib) is 
protumourigenic. For instance, the inhibition of the SHH 
pathway in pancreatic ductal adenocarcinoma (PDAC) 
murine models either chemically or genetically promotes 
tumour cell proliferation, undifferentiated phenotypes as 
well as increased vascularity, resulting in greater tumour 
burden and shorter survival (Lee et al. 2014, Rhim et al. 
2014). Similarly, SHH pathway inhibition in colorectal 
cancer (CRC) murine models leads to higher numbers 
of cells with tumour-initiating potential and accelerated 
tumour formation (Madison et  al. 2005, Gerling et  al. 
2016). Not unexpectedly, the inhibition of the hedgehog 
pathway in human PDAC and CRC was shown to yield 
rather disappointing results and patients either did not 
respond or, even worse, showed signs of faster cancer 
progression (Berlin et al. 2013, Catenacci et al. 2015, Ko 
et al. 2016). Moreover, a clinical trial using saridegib (an 
SMO inhibitor also known as IPI-926) in patients with 
PDAC was stopped due to increased tumourigenesis in the 
drug-treated group relative to the controls (Madden 2012, 
Rimkus et al. 2016) (http://investors.infi.com/static-files/
a2cbb418-8048-4f1f-94cc-dbbff91245be).
A limitation of the research presented here is 
the absence of corroborating genetic data to further 
elucidate the possible mechanisms by which SHH 
pathway inhibition leads to increased tumourigenesis in 
ACP. Unfortunately, Hesx1Cre/+;Shhflox/− mice die at birth, 
which prevents such genetic study (i.e. the Hesx1Cre/+; 
Ctnnb1loxex3/+;Shhflox/− mice cannot be generated) (Carreno 
et  al. 2017). Although ACP cellular models have been 
used, these have not been molecularly characterised and 
in our hands, the CTNNB1 mutations that characterise 
the ACP tumours are lost in the culture cells. Nonetheless, 
our cellular and molecular characterisation suggest that 
common mechanisms underlie the protumourigenic 
effects of SHH pathway inhibition in ACP, PDAC and 
CRC. We propose that in addition to the angiogenic 
effects, such inhibition prevents the exit of the cell cycle, 
resulting in higher numbers of proliferative tumour cells 
and accelerated tumourigenesis (Fig.  3G). In summary, 
using a clinically approved and widely employed 
SMO inhibitor in both the Hesx1Cre/+;Ctnnb1loxex3/+  
mice and a human xenograft model, our research 
demonstrates that the inhibition of the SHH pathway has 
a tumour-promoting effect. We conclude that the use of 
vismodegib, and potentially other SMO inhibitors may be 
contraindicated in ACP patients.
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